Related references
Note: Only part of the references are listed.Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis
Hendrik Ungefroren
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Using a Modified Polyamidoamine Fluorescent Dendrimer for Capturing Environment Polluting Metal Ions Zn2+, Cd2+, and Hg2+: Synthesis and Characterizations
Abdel Majid A. Adam et al.
CRYSTALS (2021)
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Iris Nederlof et al.
CANCERS (2021)
Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
Kitti Andreidesz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition
Tom E. H. Ogden et al.
NUCLEIC ACIDS RESEARCH (2021)
Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer
Lukas Gorecki et al.
CANCERS (2021)
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Francesco Schettini et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pleiotropic Roles of ABC Transporters in Breast Cancer
Ji He et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
Lotte van Beek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
Won-Ji Ryu et al.
PHARMACEUTICALS (2021)
Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
Masa Brumec et al.
CANCERS (2021)
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
Dey Nandini et al.
PHARMACEUTICALS (2021)
Breast Cancer Transcriptional Regulatory Network Reprogramming by using the CRISPR/Cas9 System: An Oncogenetics Perspective
Desh Deepak Singh et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2021)
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
Fokhrul Hossain et al.
CANCERS (2021)
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
Norah Aldrak et al.
CELLS (2021)
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
Jangsoon Lee et al.
BIOMEDICINES (2021)
TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
Desh Deepak Singh et al.
BIOMEDICINES (2021)
CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer
Desh Deepak Singh et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity
Travis Eisemann et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
One end to rule them all: Non-homologous end-joining and homologous recombination at DNA double-strand breaks
Michael Ensminger et al.
BRITISH JOURNAL OF RADIOLOGY (2020)
PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
Rimma Belotserkovskaya et al.
NATURE COMMUNICATIONS (2020)
Probing the Conformational Changes Associated with DNA Binding to PARP1
Johannes Rudolph et al.
BIOCHEMISTRY (2020)
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
Andrew D. Simmons et al.
BMC CANCER (2020)
Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation
Changhoon Choi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The incidence of myelodysplastic syndrome in patients receiving poly-ADP ribose polymerase inhibitors for treatment of solid tumors: A meta-analysis.
Roni Nitecki et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al.
SCIENCE (2020)
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Mauricio A. Medina et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Anna Diana et al.
CANCERS (2020)
Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions
Kha-Liang Lee et al.
CANCERS (2020)
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
Ahrum Min et al.
SCIENTIFIC REPORTS (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
Bridging of DNA breaks activates PARP2-HPF1 to modify chromatin
Silvija Bilokapic et al.
NATURE (2020)
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
Daniel Harrision et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Emerging roles of N6-methyladenosine (m6A) modification in breast cancer
Yanyan Wang et al.
CELL AND BIOSCIENCE (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
ADP-ribosylation: from molecular mechanisms to human disease
Nicolas C. Hoch et al.
GENETICS AND MOLECULAR BIOLOGY (2020)
Myelodysplastic Syndrome After Olaparib Treatment in Heavily Pretreated Ovarian Carcinoma
Murat Sari et al.
AMERICAN JOURNAL OF THERAPEUTICS (2019)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Single-Molecule Atomic Force Microscopy Study of PARP1 and PARP2 Recognition of Base Excision Repair DNA Intermediates
Maria V. Sukhanova et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee T. Keung et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target
Pei-Yu Chu et al.
CELLS (2019)
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Veronique Dieras et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Novel insights into PARPs in gene expression: regulation of RNA metabolism
Yueshuang Ke et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
PARP-1 and its associated nucleases in DNA damage response
Yijie Wang et al.
DNA REPAIR (2019)
The EMBL-EBI search and sequence analysis tools APIs in 2019
Fabio Madeira et al.
NUCLEIC ACIDS RESEARCH (2019)
CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases
Desh Deepak Singh et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2019)
PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development
Verneri Virtanen et al.
GENES (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
Kha-Liang Lee et al.
CANCERS (2019)
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard J. Appleman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
R. Tuli et al.
EBIOMEDICINE (2019)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun et al.
CANCER CELL (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Noel Clarke et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Insights into the biogenesis, function, and regulation of ADP-ribosylation
Michael S. Cohen et al.
NATURE CHEMICAL BIOLOGY (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
The comings and goings of PARP-1 in response to DNA damage
John M. Pascal
DNA REPAIR (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Emanuel Nicolas et al.
CANCERS (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
H. S. Han et al.
ANNALS OF ONCOLOGY (2018)
Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
Lotte van Andel et al.
INVESTIGATIONAL NEW DRUGS (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Andrew N. Blackford et al.
MOLECULAR CELL (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
Ethan Brill et al.
ONCOTARGET (2017)
Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer
Seth K. Rummel et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew et al.
BRITISH JOURNAL OF CANCER (2016)
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor et al.
CANCER RESEARCH (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies
Luc Dirix et al.
CLINICAL THERAPEUTICS (2016)
Identifying high quality, potent and selective inhibitors of ATM kinase: Discovery of AZD0156
B. Barlaam et al.
EUROPEAN JOURNAL OF CANCER (2016)
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
Jiayan Luo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
Ruth Plummer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
PARPs and ADP-Ribosylation: 50 Years ... and Counting
W. Lee Kraus
MOLECULAR CELL (2015)
Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation
Eva Barkauskaite et al.
MOLECULAR CELL (2015)
Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line
Federica Baldan et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
Selvi Durmus et al.
PHARMACEUTICAL RESEARCH (2015)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.
Kathy Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors
Nael M. Mostafa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
Atsushi Shibata et al.
MOLECULAR CELL (2014)
PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
Marie-France aEuro Langelier et al.
NUCLEIC ACIDS RESEARCH (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
Aisling Pierce et al.
CANCER BIOLOGY & THERAPY (2013)
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
Maria Saveria Gilardini Montani et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Appraising iniparib, the PARP inhibitor that never was-what must we learn?
Joaquin Mateo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction
Marie-France Langelier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
